Therapeutic Research

Abstract

Clinical usefulness of teneligliptin was evaluated in type 2 diabetic patients. The start of teneligliptin administration significantly lowered casual blood glucose levels by - 26.6mg/dL, HbA1c by - 1.71％, and decreased diastolic blood pressure, but did not affect body weight. There was a significant correlation of HbA1c improvement for 3 months to starting HbA1c, but not to body mass index. On the other hand, change to teneligliptin from other dipeptidyl peptidase –4 inhibitors did not cause any significant changes in HbA1c, but significantly decreased body weight and systolic blood pressure. Further studies should be necessary to clarify the differences in the effects on body weight and blood pressure among dipeptidyl peptidase –4 inhibitors.